Toshiyoshi Fujiwara
Okayama University
637 Papers
3.8K Citations
Toshiyoshi Fujiwara is an academic researcher from Okayama University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 54, co-authored 559 publications. Previous affiliations of Toshiyoshi Fujiwara include University of Texas MD Anderson Cancer Center & Kanazawa University.
Chat about Author
Papers
•Journal Article
A Retroviral Wild-type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis
Toshiyoshi Fujiwara,Elizabeth A. Grimm,Tapas Mukhopadhyay,De Wei Cai,Laurie B. Owen-Schaub,Jack A. Roth +5 more
TL;DR: It is suggested that retroviral vectors can penetrate into multiple cell layers of three-dimensional tumor masses and induce potentially therapeutic effects in spheroids treated with the wt-p53 virus.
257
Telomerase-specific replication-selective virotherapy for human cancer.
Takeshi Kawashima,Shunsuke Kagawa,Naoya Kobayashi,Yoshiko Shirakiya,Tatsuo Umeoka,Fuminori Teraishi,Masaki Taki,Satoru Kyo,Noriaki Tanaka,Toshiyoshi Fujiwara +9 more
TL;DR: The results suggest that the hTERT promoter confers competence for selective replication of TRAD in human cancer cells, an outcome that has important implications for the treatment of human cancers.
Evidence for p53-Mediated Modulation of Neuronal Viability
Hong Xiang,Daryl W. Hochman,Hideyuki Saya,Toshiyoshi Fujiwara,Philip A. Schwartzkroin,Richard S. Morrison +5 more
TL;DR: A direct relationship between p53 expression and loss of viability in CNS neurons is demonstrated using adenovirus-mediated transduction to promote neuronal cell death even in the absence of excitotoxin.
255
Therapeutic Effect of a Retroviral Wild-Type p53 Expression Vector in an Orthotopic Lung Cancer Model
Toshiyoshi Fujiwara,De Wei Cai,Renee N. Georges,Tapas Mukhopadhyay,Elizabeth A. Grimm,Jack A. Roth +5 more
TL;DR: Direct administration of a retroviral vector expressing wt-p53 may inhibit local growth in vivo of human lung cancer cells with abnormal p53 expression in nu/nu mice.
243
Patent
Methods and compositions comprising DNA damaging agents and p53
Jack A. Roth,Toshiyoshi Fujiwara,Elizabeth A. Grimm,Mukhopadhyay Tapas,Wei-Wei Zhang,Laurie B. Owen-Schaub +5 more
- 23 Feb 2004
TL;DR: In this article, a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent, was presented for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adnovirus and DNA-damaging drugs.
211